Curavit Clinical Research - DECENTRALIZED CLINICAL TRIAL
Portland, Maine, 04101, United States
NCT Number: NCT06051539
The purpose of this trial is to assess engagement, efficacy, durability, and impact on health care resource utilization of MR-001 in persons with chronic stroke who have a gait deficit after in-home/community use.
Looking for future studies?
Notify Me18 year–85 year
All sexes
Interventional
Not applicable
Portland, Maine, 04101, United States
This is a decentralized clinical trial designed to assess clinical outcomes and resulting healthcare resource utilization (HCRU) of MedRhythms' MR-001 device used by patients with chronic stroke in the home setting.
MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking in adult chronic stroke patients. MR-001 is a prescription medical device intended for use at home. The user operates the device autonomously and the therapy progresses automatically once a user engages in a session.
The MR-001 system consists of two foot sensors that measure walking, a locked touchscreen device preloaded with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries.
The primary objective of this study is to assess engagement with MR-001 walking therapy in chronic stroke patients with a gait deficit in a real world setting. The primary endpoint will be measured by session completion over the 12 week intervention period. Secondary endpoints include assessing effect on walking endurance, durability of response, and reintroduction of the intervention, as well as effect on healthcare resource utilization.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
MR-001 is an autonomous neurorehabilitation system based on the principles of Rhythmic Auditory Stimulation intended to improve walking and ambulation in adult chronic stroke patients. MR-001 is intended to be a prescription use only device for use at home/community. The user operates the MR-001 System autonomously and the therapy progresses automatically once a user engages in a session. The MR-001 system consists of two foot sensors that measure walking, a touchscreen device preloaded solely with a proprietary software application, a headset, and charging equipment. The electronic components are powered by lithium-ion rechargeable batteries. Participants are asked to walk with the device for 3 times per week for 12 weeks. Each walking session is 30 minutes in length.
Time frame: 12 weeks
The purpose of this study is to assess engagement with MR-001 walking therapy in chronic stroke patients with a gait deficit in a real world setting. Engagement will be measured as number of walking sessions observed across the 12 week intervention period.
Time frame: From baseline to end of treatment at 12 weeks
To assess whether MR-001 improves walking endurance after 12 weeks of treatment
Time frame: At 16 and 24 weeks
To assess durability of walking endurance response to MR-001 after 12 weeks of intervention
Time frame: 12 weeks
To assess whether MR-001 improves health-related quality of life in chronic stroke patients with gait deficit
Time frame: 12 weeks
To assess whether MR-001 improves activities of daily living in chronic stroke patients with gait deficit
Time frame: 12 weeks
To assess whether MR-001 improves social isolation in patients with chronic stroke with gait deficit
Time frame: 12 weeks
To assess whether MR-001 improves cognition and executive in patients with chronic stroke with gait deficit
Time frame: At 36 weeks
To assess change in walking endurance of persons who are re-introduced to a second round of treatment with the intervention
Time frame: 12 weeks
To assess change in mobility after 12 weeks of intervention
Time frame: At 36 weeks
To assess change in mobility of persons who are re-introduced to a second round of treatment with the intervention
Time frame: Baseline to 52 weeks
To assess change in all-cause healthcare resource utilization
Time frame: Baseline to 52 weeks
To assess change in all-cause hospitalizations and emergency department visits
MedRhythms, Inc.
Industry
Acronym: OrcHESTRAS
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07065292
Balance, Chronic Stroke
Afyonkarahisar, Center, Turkey (Türkiye)
View Trial DetailsNCT06895629
Chronic Stroke
Tel Aviv, Israel
View Trial DetailsNCT07656987
Brain Diseases, Cardiovascular Diseases
Istanbul, BAHCELIEVLER, Turkey (Türkiye)
View Trial DetailsNCT05953415
Chronic Stroke, Cognition Disorders
Beijing, China
View Trial Details